scholarly journals Thalamic Injury and Cognition in Multiple Sclerosis

2021 ◽  
Vol 11 ◽  
Author(s):  
Moein Amin ◽  
Daniel Ontaneda

Multiple sclerosis (MS) produces demyelination and degeneration in both gray and white matter. Both cortical and deep gray matter injury is observed during the course of MS. Among deep gray matter structures, the thalamus has received special attention, as it undergoes volume loss in different MS subtypes and is involved in the earliest form of the disease, radiologically isolated syndrome. The thalamus plays an important role as an information relay center, and involvement of the thalamus in MS has been associated with a variety of clinical manifestations in MS, including fatigue, movement disorders, pain, and cognitive impairment (CI). Similar to thalamic volume loss, CI is seen from the earliest stages of MS and is potentially one of the most debilitating manifestations of the disease. The thalamus, particularly the dorsomedial nucleus as part of the basolateral limbic circuit and anterior thalamic nuclei through connections with the prefrontal cortex, has been shown to be involved in CI. Specifically, several cognitive performance measures such as processing speed and memory correlate with thalamic volume. Thalamic atrophy is one of the most important predictors of CI in MS, and both thalamic volume, diffusion tensor imaging measures, and functional activation correlate with the degree of CI in MS. Although the exact mechanism of thalamic atrophy is not well-understood, it is hypothesized to be secondary to degeneration following white matter injury resulting in secondary neurodegeneration and neuronal loss. The thalamus may represent an ideal biomarker for studies aiming to test neuroprotective or restorative therapies aimed at cognition.

2018 ◽  
Vol 281 ◽  
pp. 78-84 ◽  
Author(s):  
Niccolò Piaggio ◽  
Simona Schiavi ◽  
Matteo Martino ◽  
Giulia Bommarito ◽  
Matilde Inglese ◽  
...  

NeuroImage ◽  
2009 ◽  
Vol 45 (1) ◽  
pp. 60-67 ◽  
Author(s):  
Kerstin Bendfeldt ◽  
Pascal Kuster ◽  
Stefan Traud ◽  
Hanspeter Egger ◽  
Sebastian Winklhofer ◽  
...  

Neurology ◽  
2018 ◽  
Vol 90 (15) ◽  
pp. e1324-e1332 ◽  
Author(s):  
Laura Gaetano ◽  
Dieter A. Häring ◽  
Ernst-Wilhelm Radue ◽  
Nicole Mueller-Lenke ◽  
Avinash Thakur ◽  
...  

ObjectiveTo study the effect of fingolimod on deep gray matter (dGM), thalamus, cortical GM (cGM), white matter (WM), and ventricular volume (VV) in patients with relapsing-remitting multiple sclerosis (RRMS).MethodsData were pooled from 2 phase III studies. A total of 2,064 of 2,355 (88%) contributed to the analysis: fingolimod 0.5 mg n = 783, fingolimod 1.25 mg n = 799, or placebo n = 773. Percentage change from baseline in dGM and thalamic volumes was evaluated with FMRIB’s Integrated Registration & Segmentation Tool; WM, cGM, and VV were evaluated with structural image evaluation using normalization of atrophy cross-sectional version (SIENAX) at months 12 and 24.ResultsAt baseline, compound brain volume (brain volume in the z block [BVz] = cGM + dGM + WM) correlated with SIENAX-normalized brain volume (r = 0.938, p < 0.001); percentage change from baseline in BVz over 2 years correlated with structural image evaluation using normalization of atrophy percentage brain volume change (r = 0.713, p < 0.001). For placebo, volume reductions were most pronounced in cGM, and relative changes from baseline were strongest in dGM. Over 24 months, there were significant reductions with fingolimod vs placebo for dGM (0.5 mg −14.5%, p = 0.017; 1.25 mg −26.6%, p < 0.01) and thalamus (0.5 mg −26.1%, p = 0.006; 1.25 mg −49.7%, p < 0.001). Reduction of cGM volume loss was not significant. Significantly less WM loss and VV enlargement were seen with fingolimod vs placebo (all p < 0.001). A high T2 lesion volume at baseline predicted on-study cGM, dGM, and thalamic volume loss (p < 0.0001) but not WM loss. Patients taking placebo with high dGM (hazard ratio [HR] 0.54, p = 0.0323) or thalamic (HR 0.58, p = 0.0663) volume at baseline were less likely to show future disability worsening.ConclusionsFingolimod significantly reduced dGM volume loss (including thalamus) vs placebo in patients with RRMS. Reducing dGM and thalamic volume loss might improve long-term outcome.


2020 ◽  
Vol 267 (5) ◽  
pp. 1536-1546 ◽  
Author(s):  
Stefano Magon ◽  
Charidimos Tsagkas ◽  
Laura Gaetano ◽  
Raihaan Patel ◽  
Yvonne Naegelin ◽  
...  

2019 ◽  
Vol 61 (1) ◽  
pp. 85-92
Author(s):  
Ramona Woitek ◽  
Fritz Leutmezer ◽  
Assunta Dal-Bianco ◽  
Julia Furtner ◽  
Gregor Kasprian ◽  
...  

Background Despite strongly overlapping patterns of clinical and histopathologic findings in primary and secondary progressive multiple sclerosis, differences concerning motor symptoms, central nervous system inflammation, atrophy, and demyelination that cannot be accounted for by lesion load alone remain to be elucidated. Purpose To evaluate the normal-appearing deep gray matter in patients with primary and secondary progressive multiple sclerosis, diffusion tensor imaging was used in this study. Material and Methods In 14 multiple sclerosis patients with primary and secondary progressive multiple sclerosis, axial echo-planar single-shot diffusion tensor imaging sequences with 32 diffusion-encoding directions and axial FLAIR sequences were acquired on a 3T system using an eight-channel SENSE head coil. FLAIR hyperintense multiple sclerosis lesions were outlined semi-automatically and normal-appearing deep gray matter was outlined manually (caudate nucleus, globus pallidus, putamen, thalamus, substantia nigra, and red nucleus). Fractional anisotropy and mean diffusivity values within the normal-appearing deep gray matter for the two groups were compared. Results Interhemispheric differences in mean diffusivity values (but not in fractional anisotropy), were significantly higher in primary progressive multiple sclerosis than in secondary progressive multiple sclerosis for the substantia nigra ( P = 0.04) and the putamen ( P = 0.021). Volumes, mean diffusivity, or fractional anisotropy of the remaining normal-appearing deep gray matter did not differ significantly. Conclusion This study showed a higher interhemispheric difference in the mean diffusivity in the substantia nigra and putamen in patients with primary progressive multiple sclerosis than in those with secondary progressive multiple sclerosis. These changes may represent edema, as well as axonal and myelin loss that can affect the normal-appearing deep gray matter of the two hemispheres differently and may point to differences in the laterality of motor symptoms.


2012 ◽  
Vol 68 (6) ◽  
pp. 1932-1942 ◽  
Author(s):  
Efrosini Z. Papadaki ◽  
Vasileios C. Mastorodemos ◽  
Emmanouil Z. Amanakis ◽  
Konstantinos C. Tsekouras ◽  
Antonis E. Papadakis ◽  
...  

2016 ◽  
Vol 27 (1) ◽  
pp. 107-113 ◽  
Author(s):  
Niels Bergsland ◽  
Eleonora Tavazzi ◽  
Maria Marcella Laganà ◽  
Francesca Baglio ◽  
Pietro Cecconi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document